Unlabelled: SPECT imaging of the dopamine transporter is now an alternative to PET in the quantification of nigrostriatal dopaminergic function. We compared [123I] beta CIT-FP/SPECT and [18F]FDOPA/PET in the assessment of nigrostriatal dopaminergic function in Parkinson's disease (PD) and normal aging.

Methods: We studied 12 mildly affected PD patients (mean age: 61.0 +/- 13.2 yr; H&Y Stage I-II) with both [123I] beta CIT-FP and [18F]FDOPA. Fifteen normal volunteers (mean age: 45.5 +/- 22.1 yr) served as controls for both tracers. We measured the striato-occipital ratio (SOR) for both tracers at approximately 100 min postinjection.

Results: We found a highly significant correlation between SOR measures obtained for both tracers (r = 0.79, p < 0.0001). In normal volunteers a significant age-related decline in striatal uptake was noted with [123I] beta CIT-FP (r = -0.56, p < 0.04) but not with [18F]FDOPA. SOR values for both tracers discriminated PD patients from controls with comparable accuracy (F[1,25] = 52.1 and 53.0, p < 0.0001 for [123I] beta CIT-FP and [18F]FDOPA, respectively). UPDRS motor ratings correlated with SOR values obtained by both imaging techniques (r = -0.69 and -0.60, p < 0.04 for [123I] beta CIT-FP and [18F]FDOPA, respectively).

Conclusion: These results indicate that [123I] beta CIT-FP/SPECT can provide quantitative descriptors of presynaptic dopaminergic function comparable to those obtained with [18F]FDOPA/PET.

Download full-text PDF

Source

Publication Analysis

Top Keywords

[123i] beta
24
beta cit-fp
16
nigrostriatal dopaminergic
12
dopaminergic function
12
cit-fp [18f]fdopa
12
beta cit-fp/spect
8
normal volunteers
8
sor values
8
[123i]
6
beta
6

Similar Publications

Background: While previous imaging studies have generally shown normal striatal dopamine transporter (DAT) binding in essential tremor (ET), emerging evidence suggests a partial dopaminergic mechanism in this condition and an epidemiological link between ET and Parkinson's disease (PD). This link seems particularly meaningful in ET patients with additional neurological signs, such as slowness of movements, rigidity, or rest tremor (ET+).

Objectives: To investigate the potential dopaminergic pathophysiology of ET+ and to compare it to PD.

View Article and Find Full Text PDF

Underrecognized Utility of I-BMIPP in CAD Diagnosis Outside of Japan.

Ann Nucl Cardiol

October 2024

Department of Radiology, Sakakibara Heart Institute, Tokyo, Japan.

Article Synopsis
  • * Reduced uptake of I-BMIPP can indicate issues related to heart conditions, especially in patients with coronary artery disease (CAD).
  • * While I-BMIPP is widely used in Japan due to its practical benefits, such as no need for stress tests, its use is limited elsewhere due to regulatory hurdles and supply issues, highlighting the need for broader adoption internationally.
View Article and Find Full Text PDF

Longitudinal decline in DAT binding in Parkinson's disease: connections with sleep disturbances.

BMC Med

November 2024

Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou , Zhejiang, 310009, China.

Article Synopsis
  • The study examined how the dysfunction of the nigrostriatal dopamine system affects sleep disturbances in newly diagnosed Parkinson's disease patients, focusing on excessive daytime sleepiness and probable RBD.
  • Data was collected from 621 patients over four years through established sleep scales and dopamine transporter imaging.
  • Results showed a negative correlation between dopamine transporter binding ratios and sleep issues, suggesting that dopamine dysfunction and genetic factors (like the alpha-synuclein gene) significantly contribute to sleep disturbances in these patients.
View Article and Find Full Text PDF

Potential Application of the Myocardial Scintigraphy Agent [I]BMIPP in Colon Cancer Cell Imaging.

Int J Mol Sci

July 2024

Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.

[I]β-methyl-p-iodophenyl-pentadecanoic acid ([I]BMIPP), which is used for nuclear medicine imaging of myocardial fatty acid metabolism, accumulates in cancer cells. However, the mechanism of accumulation remains unknown. Therefore, this study aimed to elucidate the accumulation and accumulation mechanism of [I]BMIPP in cancer cells.

View Article and Find Full Text PDF

Predictors of appropriate therapies delivered by the implantable cardioverter-defibrillator in patients with coronary artery disease during long-term period.

Int J Cardiovasc Imaging

September 2024

Academician of the Russian Academy of Sciences, Director, Department of Surgical Arrhythmology and Cardiac Pacing, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russian Federation, Kievskaya st., 111a, Tomsk, 634012, Russia.

This prospective study aimed to investigate the ability of cardiac autonomic nervous system (CANS) activity assessment to predict appropriate implantable cardioverter-defibrillator (ICD) therapy in patients with coronary artery disease (CAD) during long-term follow-up period. We enrolled patients with CAD and ICD implantation indications that included both secondary and primary prevention of sudden cardiac death. Before ICD implantation CANS was assessed by using heart rate variability (HRV), myocardium scintigraphy with I-meta-iodobenzylguanidine (I-MIBG) and erythrocyte membranes β-adrenoreactivity (EMA).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!